PDCD1 and non-small cell lung carcinoma: Immune checkpoint inhibitors (ICIs) targeting programmed cell death-1 (PD-1) and its ligand programmed cell death ligand-1 (PD-L1) have significantly improved long-term survival in PD-L1 selected patients with advanced non-small cell lung cancer (NSCLC) [1, 2].